Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 12 of the 16 sources its claims cite were checked for support.
Abstract
BACKGROUND: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19. METHODS: This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States. Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2. RESULTS: The trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each group). More than 96% of participants received both injections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline. Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI], 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3.3 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% (95% CI, 89.3 to 96.8%; P<0.001). Efficacy was similar across key secondary analyses, including assessment 14 days after the first dose, analyses that included participants who had evidence of SARS-CoV-2 infection at baseline, and analyses in participants 65 years of age or older. Severe Covid-19 occurred in 30 participants, with one fatality; all 30 were in the placebo group. Moderate, transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group. Serious adverse events were rare, and the incidence was similar in the two groups. CONCLUSIONS: The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).
Overview
CoChat Summary
TL;DR
In a phase 3 U.S. trial, mRNA-1273 (100 μg given as two doses 28 days apart) prevented symptomatic Covid-19 with 94.1% efficacy and showed no safety concerns beyond transient reactogenicity. Severe Covid-19 occurred in 30 participants, all in the placebo group.
Key findings
- Among 30,420 randomized participants (15,210 per group), the primary per-protocol analysis found symptomatic Covid-19 in 11 mRNA-1273 recipients vs. 185 placebo recipients (3.3 vs. 56.5 per 1000 person-years), for vaccine efficacy of 94.1% (95% CI, 89.3 to 96.8; P<0.001).
- Severe Covid-19 occurred in 30 participants, all in the placebo group (vaccine efficacy 100%; 95% CI could not be estimated to 1.0), including one Covid-19–related death.
- Solicited local adverse events were more frequent with mRNA-1273 after dose 1 (84.2% vs. 19.8%) and dose 2 (88.6% vs. 18.8%); solicited systemic events were also more frequent after dose 1 (54.9% vs. 42.2%) and dose 2 (79.4% vs. 36.5%). Serious adverse events were similar (0.6% in both groups).
- Efficacy was similar across subgroups, including 95.6% among participants 18 to <65 years, 86.4% among those ≥65 years, and 97.5% in communities of color.
Methods
- Phase 3 randomized, observer-blinded, placebo-controlled trial conducted at 99 U.S. centers; adults at high risk for SARS-CoV-2 infection or severe Covid-19 were assigned 1:1 to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart.
- The primary end point was prevention of symptomatic Covid-19 with onset at least 14 days after the second injection in per-protocol participants who were seronegative at baseline; cases were adjudicated, and vaccine efficacy was defined as 1 minus the hazard ratio (mRNA-1273 vs. placebo) using a stratified Cox proportional hazards model.
- Safety was assessed in all participants who received at least one injection, including solicited local and systemic adverse events for 7 days after each injection, unsolicited adverse events for 28 days, and serious/medically attended events through day 759.
Limitations
- Stated: short duration of safety and efficacy follow-up (median 64 days after the second dose; 2-year follow-up planned); no identified correlate of protection; insufficient data to assess asymptomatic infection; limited cases in older adults, racial/ethnic minorities, and previously infected persons; pregnant women and children were excluded.
- Stated: the trial was not designed to evaluate single-dose efficacy; rare adverse events are hard to detect given sample size; long-term risk of enhanced respiratory disease after exposure remains unknown.
- Evident: the primary analysis reflects only short-term follow-up, so durability of protection is unknown; subgroup estimates have wide confidence intervals (e.g., ≥65 years: 86.4%, 95% CI 61.4 to 95.2).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 3 Not checked · 79 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The efficacy of mRNA-1273 is in line with that of the recently reported BNT162b2 mRNA vaccine. 16”
What the sources say
- Supportedcites [16] 16. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 Covid-19 vaccine. N Engl J Med 2020; 383: 2603-15. source
The Abstract Results report that BNT162b2 was 95% effective in preventing Covid-19, and the Discussion likewise describes 95% efficacy after two doses. The comparison with mRNA-1273 is the citing authors’ own framing; this source supplies the BNT162b2 efficacy result. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The reactogenicity associated with immunization with mRNA-1273 in this trial is similar to that in the phase 1 data reported previously. 1,4”
What the sources say
- Supportedcites [1] 1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020; 383: 1920-31. source
The Methods identify this as a phase 1 trial of mRNA-1273 that evaluated reactogenicity. The Results (Vaccine Safety; page unavailable) report its reactogenicity findings, so it supports the citation’s reference to previously reported phase 1 data. (LLM, conf=0.88)
- Supportedcites [4] 4. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; 383: 2427-38. source
The Discussion states that the authors observed no systematic differences in reactogenicity between the older participants in this study and younger mRNA-1273 recipients reported previously. It cautions that the small groups do not permit meaningful formal statistical comparisons, but the citing sentence makes only a qualitative comparison. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the overall population, the incidence of treatment-related severe adverse events was higher in the mRNA-1273 group (71 participants [0.5%]) than in the placebo group (28 participants [0.2%]) (Tables S8 and S15).”
plainstates an associationn = 71- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events that were deemed by the trial team to be related to the vaccine or placebo were reported among 4.5% of participants in the placebo group and 8.2% in the mRNA-1273 group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The relative incidence of these adverse events according to vaccine group was not affected by age.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 88 claims and every source verdict.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [44]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently licensed vaccines have shown efficacies of up to 95% in preventing laboratory-confirmed infection over the first few months after vaccination61–63”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two mRNA vaccines approved to date show efficacy even after only one dose, when non-NAbs and moderate T helper 1 cell responses are detectable, but almost no NAbs.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Robust CD4+ and CD8+ T cell memory is induced after COVID-19,22,39, 40, 41 and multiple COVID-19 vaccines elicit CD4+ and CD8+ T cell responses.26,42, 43, 44, 45”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [44]
Experimental — accuracy not yet measured
43 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Self-citationRNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
The COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Self-citationDeveloping Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citation
Cited by
Items 1,701–1,800 of 10,906
Gau, B. C., Dawdy, A., Wang, H. L., Bare, B., Castaneda, C. H., Friese, O. V., Thompson, M. S., Lerch, T. F., Cirelli, D. J., & Rouse, J. C. (2023) · Scientific Reports · doi:10.1038/s41598-023-36193-2 · Cited by 49
Grasselli, G., Zanella, A., Carlesso, E., Florio, G., Canakoglu, A., Bellani, G., Bottino, N., Cabrini, L., Castelli, G. P., Catena, E., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.38871 · Cited by 55
Stouten, V., Hubin, P., Haarhuis, F., van Loenhout, J. A. F., Billuart, M., Brondeel, R., Braeye, T., Oyen, H. J. V., Wyndham-Thomas, C., & Catteau, L. (2022) · Viruses · doi:10.3390/v14040802 · Cited by 53
Qassim, S. H., Chemaitelly, H. S., Ayoub, H. H., AlMukdad, S., Tang, P., Hasan, M. R., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Rahim, H. F. A., et al. (2022) · Journal of Travel Medicine · doi:10.1093/jtm/taac068 · Cited by 50
Abraham, N., Spruin, S., Rossi, T. M., FIREMAN, B. H., Zafack, J. G., Blaser, C., Shaw, A. K., Hutchings, K., & Ogunnaike-Cooke, S. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.05.048 · Cited by 45
Stewart-Jones, G., Elbashir, S. M., Wu, K., Lee, D., Renzi, I., Ying, B., Koch, M., Sein, C. E., Choi, A., Whitener, B. M., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adf4100 · Cited by 56
Jung, S., Jeon, J. J., Kim, Y. H., Choe, S. J., & Lee, S. (2024) · Nature Communications · doi:10.1038/s41467-024-50656-8 · Cited by 59
Duan, X., Zhang, Y., Guo, M., Fan, N., Chen, K., Qin, S., Xiao, W., Zheng, Q., Huang, H., Wei, X., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.08.015 · Cited by 46
Berec, L., Šmíd, M., Přibylová, L., Májek, O., Pavlík, T., Jarkovský, J., Zajíček, M., Weiner, J., Barusová, T., & Trnka, J. (2022) · PLoS ONE · doi:10.1371/journal.pone.0270801 · Cited by 47
Tung, T., Lin, X., Chen, Y., Zhang, M., & Zhu, J. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2016401 · Cited by 48
The Use of COVID-19 Vaccines in Patients with SLE
Tang, W., Gartshteyn, Y., Ricker, E., Inzerillo, S., Murray, S., Khalili, L., & Askanase, A. (2021) · Current Rheumatology Reports · doi:10.1007/s11926-021-01046-2 · Cited by 49
Dębska-Ślizień, A. M., Ślizień, Z., Muchlado, M., et al. (2021) · Vaccines · doi:10.3390/vaccines9101165 · Cited by 46
COVID-19 Vaccination Scenarios: A Cost-Effectiveness Analysis for Turkey
Hagens, A., İnkaya, A. Ç., Yıldırak, K., Sancar, M., van der Schans, J., Sancar, A. A., Ünal, S., Postma, M. J., & Yeğenoğlu, S. (2021) · Vaccines · doi:10.3390/vaccines9040399 · Cited by 51
Ying, B., Darling, T. L., Desai, P., Liang, C.-Y., Dmitriev, I. P., Soudani, N., Bricker, T. L., Kashentseva, E. A., Harastani, H., Raju, S., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01743-x · Cited by 54
Barazzone, G. C., Teixeira, A. F., Azevedo, B. O. P., Damiano, D. K., Oliveira, M. P., Nascimento, A. L. T. O., & Lopes, A. P. Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.760291 · Cited by 59
Crespo, M., Barrilado-Jackson, A., Padilla, E., Eguía, J., Echeverría-Esnal, D., Cao, H., Faura, A., Folgueiras, M., Solà-Porta, E., Pascual-Guàrdia, S., et al. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16854 · Cited by 52
Reischig, T., Kacer, M., Vlas, T., Drenko, P., Kielberger, L., Machova, J., Topolčan, O., Kučera, R., & Kormunda, S. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16902 · Cited by 53
Hwang, Y., Shepherd, S. J., Kim, D., Mukalel, A. J., Mitchell, M. J., Issadore, D., & Lee, D. (2024) · ACS Nano · doi:10.1021/acsnano.4c12965 · Cited by 58
Intapiboon, P., Seepathomnarong, P., Ongarj, J., Surasombatpattana, S., Uppanisakorn, S., Mahasirimongkol, S., Sawaengdee, W., Phumiamorn, S., Sapsutthipas, S., Sangsupawanich, P., et al. (2021) · Vaccines · doi:10.3390/vaccines9121375 · Cited by 51
Divalent siRNAs are bioavailable in the lung and efficiently block SARS-CoV-2 infection
Hariharan, V. N., Shin, M., Chang, C., O’Reilly, D., Biscans, A., Yamada, K., Guo, Z., Somasundaran, M., Tang, Q., Monopoli, K. R., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2219523120 · Cited by 49
SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs
Iketani, S., & Ho, D. D. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.03.008 · Cited by 51
Sharma, M., Batra, K., & Batra, R. (2021) · Healthcare · doi:10.3390/healthcare9101273 · Cited by 53
Tobaiqy, M. A., MacLure, K., Elkout, H., & Stewart, D. C. (2021) · Vaccines · doi:10.3390/vaccines9111326 · Cited by 46
Andretto, V., Dusi, S., Zilio, S., Repellin, M., Kryza, D., Ugel, S., & Lollo, G. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115080 · Cited by 52
Andrejko, K. L., Pry, J., Myers, J. F., Jewell, N. P., Openshaw, J., Watt, J., Jain, S., Lewnard, J. A., California COVID-19 Case-Control Study Team, Samani, H., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab640 · Cited by 46
Booster dose of mRNA vaccine augments waning T cell and antibody responses against SARS-CoV-2
Kurt, F. G. Ö., Lepper, A., Gerhards, C., Roemer, M., Lasser, S., Arkhypov, I., Bitsch, R., Bugert, P., Altevogt, P., Gouttefangeas, C., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1012526 · Cited by 53
Servellita, V., Morris, M. K., Sotomayor-González, A., Gliwa, A. S., Torres, E., Brazer, N., Zhou, A. Y., Hernandez, K., Sankaran, M., Wang, B., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-021-01041-4 · Cited by 48
COVID-induced thyroid autoimmunity
Brancatella, A., Viola, N., Santini, F., & Latrofa, F. (2023) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2023.101742 · Cited by 55
Intranasal prime-boost RNA vaccination elicits potent T cell response for lung cancer therapy
Li, H., Hu, Y., Li, J., He, J., Yu, G., Wang, J., & Lin, X. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02191-1 · Cited by 57
Risk of COVID-19 breakthrough infection and hospitalization in individuals with comorbidities
Smits, P. D., Gratzl, S., Simonov, M., Nachimuthu, S., Cartwright, B. M. G., Wang, M. D., Baker, C., Rodriguez, P., Bogiages, M., Althouse, B. M., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.02.038 · Cited by 49
Shaw, C. A., August, A., Bart, S., Jackson-Booth, P.-G., Knightly, C., Brasel, T., Weaver, S. C., Zhou, H., & Panther, L. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.04.064 · Cited by 51
Self-citationABE8e adenine base editor precisely and efficiently corrects a recurrent COL7A1 nonsense mutation
Sheriff, A., Guri, I., Żebrowska-Różańska, P., Llopis-Hernández, V., Brooks, I. R., Tekkela, S., Subramaniam, K. S., Gebrezgabher, R., Naso, G., Petrova, A., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-24184-8 · Cited by 51
Novel formulations and drug delivery systems to administer biological solids
Zhang, Y., Davis, D. A., AboulFotouh, K., Wang, J., Williams, D., Bhambhani, A., Zakrewsky, M., Maniruzzaman, M., Cui, Z., & Williams, R. O. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.02.011 · Cited by 52
Huang, X., Yu, M., Fu, G., Lan, G., Li, L., Yang, J., Qiao, Y., Zhao, J., Qian, H., Zhang, X., et al. (2021) · JMIR Public Health and Surveillance · doi:10.2196/31125 · Cited by 47
Social and structural determinants of COVID-19 vaccine uptake among racial and ethnic groups
Peña, J. M., Schwartz, M., Hernandez‐Vallant, A., & Sánchez, G. R. (2023) · Journal of Behavioral Medicine · doi:10.1007/s10865-023-00393-y · Cited by 54
Therapeutic strategies to fight COVID‐19: Which is the status artis?
Scavone, C., Mascolo, A., Rafaniello, C., Sportiello, L., Trama, U., Zoccoli, A., Bernardi, F. F., Racagni, G., Berrino, L., Castaldo, G., et al. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15452 · Cited by 48
Ma, Z., Wong, S. W., Forgham, H., Esser, L., Lai, M., Leiske, M. N., Kempe, K., Sharbeen, G., Youkhana, J., Mansfeld, F. M., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121539 · Cited by 48
Wang, L., Davis, P. B., Kaelber, D. C., & Xu, R. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12669 · Cited by 46
Rolfo, C., Meshulami, N., Russo, A., Krammer, F., García‐Sastre, A., Mack, P. C., Gomez, J. E., Bhardwaj, N., Benyounes, A., Sirera, R., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.11.001 · Cited by 53
Spike protein of SARS-CoV-2 variants: a brief review and practical implications
Candido, K. L., Eich, C. R., de Fariña, L. O., Kadowaki, M. K., Silva, J. L. D. C., Maller, A., & Simão, R. D. C. G. (2022) · Brazilian Journal of Microbiology · doi:10.1007/s42770-022-00743-z · Cited by 50
Broad-spectrum pan-genus and pan-family virus vaccines
Tan, C. W., Valkenburg, S., Poon, L. L. M., & Wang, L. (2023) · Cell Host & Microbe · doi:10.1016/j.chom.2023.05.017 · Cited by 44
COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria
Gerber, G. F., Yuan, X., Yu, J. M., et al. (2021) · Blood · doi:10.1182/blood.2021011548 · Cited by 46
Tabarsi, P., Anjidani, N., Shahpari, R., Mardani, M., Sabzvari, A., Yazdani, B., Kafi, H., Fallah, N., Ebrahimi, A., Taheri, A., et al. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2022.09.001 · Cited by 53
Comprehensive literature review on COVID-19 vaccines and role of SARS-CoV-2 variants in the pandemic
Yap, C., Ali, A., Prabhakar, A., Prabhakar, A., Pal, A., Lim, Y. Y., & Kakodkar, P. (2021) · Therapeutic Advances in Vaccines and Immunotherapy · doi:10.1177/25151355211059791 · Cited by 54
Injectable Slow-Release Hydrogel Formulation of a Plant Virus-Based COVID-19 Vaccine Candidate
Nkanga, C. I., Ortega-Rivera, O. A., Shin, M. D., Moreno‐Gonzalez, M. A., & Steinmetz, N. F. (2022) · Biomacromolecules · doi:10.1021/acs.biomac.2c00112 · Cited by 47
Caring for older adults during the COVID-19 pandemic
Prendki, V., Tiseo, G., & Falcone, M. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2022.02.040 · Cited by 27
Poustforoosh, A., Hashemipour, H., Tüzün, B., Azadpour, M., Faramarz, S., Pardakhty, A., Mehrabani, M., & Nematollahi, M. H. (2022) · Current Microbiology · doi:10.1007/s00284-022-02921-6 · Cited by 46
Röltgen, K., Nielsen, S. C. A., Arunachalam, P. S., Yang, F., Hoh, R. A., Wirz, O. F., Lee, A. S., Gao, F., Mallajosyula, V., Li, C., et al. (2021) · doi:10.1101/2021.04.05.21254952 · Cited by 45
Waning effectiveness of SARS-CoV-2 mRNA vaccines in older adults: a rapid review
Nanishi, E., Levy, O., & Ozonoff, A. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2045857 · Cited by 47
Novak, N., Tordesillas, L., & Cabanillas, B. (2021) · International Reviews of Immunology · doi:10.1080/08830185.2021.1939696 · Cited by 50
Dromedary camel nanobodies broadly neutralize SARS-CoV-2 variants
Hong, J., Kwon, H. J., Cachau, R., Chen, C. Z., Butay, K. J., Duan, Z., Li, D., Ren, H., Liang, T., Zhu, J., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2201433119 · Cited by 49
Braeye, T., Cornelissen, L., Catteau, L., Haarhuis, F., Proesmans, K., Ridder, K. D., Djiena, A., Mahieu, R., Leeuw, F. D., Dreuw, A., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.08.060 · Cited by 48
Directing the Way—Receptor and Chemical Targeting Strategies for Nucleic Acid Delivery
Steffens, R. C., & Wagner, E. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03385-w · Cited by 53
Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences
Hoteit, R., & Yassine, H. M. (2022) · Vaccines · doi:10.3390/vaccines10060919 · Cited by 51
Giesen, N., Sprute, R., Rüthrich, M. M., Khodamoradi, Y., Mellinghoff, S. C., Beutel, G., Lueck, C., Koldehoff, M., Hentrich, M., Sandherr, M., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.01.033 · Cited by 50
Prevention of COVID-19 by mRNA-based vaccines within the general population of California
Andrejko, K. L., Pry, J., Myers, J. F., Jewell, N. P., Openshaw, J., Watt, J., Jain, S., & Lewnard, J. A. (2021) · medRxiv · doi:10.1101/2021.04.08.21255135 · Cited by 43
The Development of SARS-CoV-2 Variants: The Gene Makes the Disease
Pérez-Gómez, R. (2021) · Journal of Developmental Biology · doi:10.3390/jdb9040058 · Cited by 48
Li, Y., Bi, Y., Xiao, H., Yao, Y., Liu, X., Hu, Z., Duan, J., Yang, Y., Li, Z., Li, Y., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1887767 · Cited by 45
Early human B cell signatures of the primary antibody response to mRNA vaccination
Kardava, L., Rachmaninoff, N., Lau, W. W., Buckner, C. M., Trihemasava, K., de Assis, F. L., Wang, W., Zhang, X., Wang, Y., Chiang, C.-I., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2204607119 · Cited by 44
Chrissian, A. A., Oyoyo, U. E., Patel, P., Beeson, W. L., Loo, L. K., Tavakoli, S., & Dubov, A. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.04.046 · Cited by 46
COVID-19 Vaccination Associated With Reduced Postoperative SARS-CoV-2 Infection and Morbidity
Prasad, N. K., Lake, R., Englum, B. R., Turner, D. J., Siddiqui, T., Mayorga‐Carlin, M., Sorkin, J. D., & Lal, B. K. (2021) · Annals of Surgery · doi:10.1097/sla.0000000000005176 · Cited by 48
Nanoparticles in clinical trials of COVID-19: An update
Rauf, A., Abu‐Izneid, T., Khalil, A. A., Hafeez, N., Olatunde, A., Rahman, M. M., Semwal, P., Al-Awthan, Y. S., Bahattab, O. S., Khan, I. N., et al. (2022) · International Journal of Surgery · doi:10.1016/j.ijsu.2022.106818 · Cited by 49
Polyplex designs for improving the stability and safety of RNA therapeutics
Uchida, S., Lau, C. Y. J., Oba, M., & Miyata, K. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114972 · Cited by 52
Yi, J., Lei, X., Guo, F., Chen, Q., Chen, X., Zhao, K., Zhu, C., Cheng, X., Lin, J., Yin, H., et al. (2023) · Antiviral Research · doi:10.1016/j.antiviral.2023.105618 · Cited by 46
Montesinos, I., Dahma, H., Wolff, F., Dauby, N., Delaunoy, S., Wuyts, M., Detemmerman, C., Duterme, C., Vandenberg, O., Martin, C., et al. (2021) · Journal of Clinical Virology · doi:10.1016/j.jcv.2021.104988 · Cited by 48
Hvidt, A. K., Baerends, E. A. M., Søgaard, O. S., Stærke, N. B., Raben, D., Reekie, J., Nielsen, H., Johansen, I. S., Wiese, L., Benfield, T., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.994160 · Cited by 46
COVID ‐19 and plasma cells: Is there long‐lived protection?*
Nguyen, D. C., Lamothe, P. A., Woodruff, M. C., Saini, A. S., Faliti, C. E., Sanz, I., & Lee, F. E.-H. (2022) · Immunological Reviews · doi:10.1111/imr.13115 · Cited by 53
Nanomaterials in diagnostics, imaging and delivery: Applications from COVID-19 to cancer
Bardhan, N. M. (2022) · MRS Communications · doi:10.1557/s43579-022-00257-7 · Cited by 49
Yin, J., Chen, Y., Li, Y., Wang, C., & Zhang, X. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.10.005 · Cited by 50
Lymphadenopathy after BNT162b2 Covid-19 Vaccine: Preliminary Ultrasound Findings
Granata, V., Fusco, R., Setola, S. V., et al. (2021) · Biology · doi:10.3390/biology10030214 · Cited by 45
Guglielmi, V., Colangeli, L., D’Adamo, M., & Sbraccia, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063183 · Cited by 49
Unleashing the power of CAR-M therapy in solid tumors: a comprehensive review
Morva, A., Arroyo, A. B., Andreeva, L., Tapia‐Abellán, A., & Luengo‐Gil, G. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1615760 · Cited by 53
Skowronski, D. M., Setayeshgar, S., Zou, M., Prystajecky, N., Tyson, J. R., Galanis, E., Naus, M., Patrick, D. M., Sbihi, H., El Adam, S., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab616 · Cited by 45
Rafati, A., Pasebani, Y., Jameie, M., Yang, Y., Jameie, M., Ilkhani, S., Amanollahi, M., Sakhaei, D., Rahimlou, M., & Kheradmand, A. (2023) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2023.0160 · Cited by 45
Kawai, A., Shimizu, T., Tanaka, H., Shichinohe, S., Anindita, J., Hirose, M., Kawahara, E., Senpuku, K., Shimooka, M., Mai, L. T. Q., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.12.032 · Cited by 53
Kawaguchi, Y., Kimura, M., Karaki, T., Tanaka, H., Ono, C., Ishida, T., Matsuura, Y., Hirai, T., Akita, H., Shimizu, T., et al. (2025) · ACS Nano · doi:10.1021/acsnano.5c10648 · Cited by 59
Roberts, C. H., Brindle, H. E., Rogers, N. T., Eggo, R. M., Enria, L., & Lees, S. S. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.745630 · Cited by 53
More than a delivery system: the evolving role of lipid-based nanoparticles
Karmaker, S., Rosales, P. D., Tirumuruhan, B., Viravalli, A., & Boehnke, N. (2025) · Nanoscale · doi:10.1039/d4nr04508d · Cited by 61
Meulewaeter, S., Aernout, I., Deprez, J., Engelen, Y., Velder, M. D., Franceschini, L., Breckpot, K., Calenbergh, S. V., Asselman, C., Boucher, K. L., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.04.052 · Cited by 48
Profiling vaccine believers and skeptics in nurses: A latent profile analysis
Leung, C. L. K., Li, K., Wei, V. W. I., Tang, A., Wong, S. Y. S., Lee, S. S., & Kwok, K. O. (2021) · International Journal of Nursing Studies · doi:10.1016/j.ijnurstu.2021.104142 · Cited by 54
Human Milk SARS-CoV-2 Antibodies up to 6 Months After Vaccination
Perez, S. E., Centeno, L. D. L., Cheng, W. A., Ruiz, C. J. M., Lee, Y., Congrave‐Wilson, Z., Powell, R. L. R., Stellwagen, L. M., & Pannaraj, P. S. (2022) · PEDIATRICS · doi:10.1542/peds.2021-054260 · Cited by 47
Hong, L., Alu, A., Yang, J., Ren, W., He, C., Lan, T., He, X., Yang, L., Li, J., Wang, Z., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01002-1 · Cited by 43
Kantarcıoğlu, B., Iqbal, O., Walenga, J. M., Lewis, B., Lewis, J., Carter, C. A., Singh, M., Lievano, F. A., Tafur, A. J., Ramacciotti, E., et al. (2021) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296211021498 · Cited by 49
Cutaneous adverse reactions of COVID ‐19 vaccines: A systematic review
Qaderi, K., Golezar, M. H., Mardani, A., Mallah, M. A., Moradi, B., Kavoussi, H., Shamsabadi, A., & Golezar, S. (2022) · Dermatologic Therapy · doi:10.1111/dth.15391 · Cited by 53
Fabricius, D., Ludwig, C., Scholz, J. A. M., Rode, I., Tsamadou, C., Jacobsen, E., Winkelmann, M., Grempels, A., Lotfi, R., Janda, A., et al. (2021) · Vaccines · doi:10.3390/vaccines9080918 · Cited by 46
Impact of COVID-19 on Pediatric Immunocompromised Patients
Connelly, J. A., Chong, H., Esbenshade, A. J., Frame, D. G., Failing, C., Secord, E. A., & Walkovich, K. J. (2021) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2021.05.007 · Cited by 46
Prevention of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines
Santacatterina, M., Sanders, J. W., & Weintraub, W. S. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2113575 · Cited by 44
van Oosten, L., Altenburg, J. J., Fougeroux, C. E., Geertsema, C., van den End, F., Evers, W. A. C., Westphal, A. H., Lindhoud, S., van den Berg, W., Swarts, D. C., et al. (2021) · mBio · doi:10.1128/mbio.01813-21 · Cited by 44
Computational design of mRNA vaccines
Kim, Y.-A., Mousavi, K., Yazdi, A. K., Zwierzyna, M., Cardinali, M., Fox, D. M., Peel, T., Coller, J., Aggarwal, K., & Maruggi, G. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.07.024 · Cited by 51
Kubara, K., Yamazaki, K., Miyazaki, T., Kondo, K., Kurotaki, D., Tamura, T., & Suzuki, Y. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.01.020 · Cited by 55
COVID-19 Vaccines in Cancer Patients. Seropositivity and Safety. Systematic Review and Meta-Analysis
Cavanna, L., Citterio, C., & Toscani, I. (2021) · Vaccines · doi:10.3390/vaccines9091048 · Cited by 45
A Series of Patients With Myocarditis Following SARS-CoV-2 Vaccination With mRNA-1279 and BNT162b2
Dickey, J. B., Albert, E., Badr, M., et al. (2021) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2021.06.003 · Cited by 44
RETRACTED: The Safety of COVID-19 Vaccinations—We Should Rethink the Policy
Walach, H., Klement, R. J., & Aukema, W. (2021) · Vaccines · doi:10.3390/vaccines9070693 · Cited by 70
RetractedSzubert, A. J., Pollock, K. M., Cheeseman, H. M., Alagaratnam, J., Bern, H., Bird, O., Boffito, M., Byrne, R., Cole, T., Cosgrove, C. A., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101823 · Cited by 46
Longitudinal Systemic and Mucosal Immune Responses to SARS-CoV-2 Infection
Wright, P. F., Prevost-Reilly, A., Natarajan, H., Brickley, E. B., Connor, R. I., Wieland‐Alter, W., Miele, A. S., Weiner, J. A., Nerenz, R. D., & Ackerman, M. E. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac065 · Cited by 46
SARS-CoV-2 Vaccines: Where Are We Now?
Flanagan, K. L., MacIntyre, C. R., McIntyre, P. B., & Nelson, M. R. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.07.016 · Cited by 46
Akache, B., Renner, T. M., Tran, A., Deschatelets, L., Dudani, R., Harrison, B. A., Duque, D., Haukenfrers, J., Rossotti, M. A., Gaudreault, F., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-01363-7 · Cited by 47
Little, J. S., Tandon, M., Hong, J., Nadeem, O., Sperling, A. S., Raje, N. S., Munshi, N. C., Frigault, M. J., Barmettler, S., & Hammond, S. P. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010524 · Cited by 50
Metadata
- Authors
- Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola, J., Polakowski, L., Ledgerwood, J., Graham, B. S., Bennett, H., Pajon, R., Knightly, C., Leav, B., Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J., & Zaks, T.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital (L.R.B.), Boston, and Moderna, Cambridge (H.B., R.P., C.K., B.L., W.D., H.Z., S.H., M.I., J. Miller, T.Z.) — both in Massachusetts; Baylor College of Medicine (H.M.E.S.) and Centex Studies (J.S.) — both in Houston; Meridian Clinical Research, Savannah (B.E., S.K., A.B.), and Emory University (N.R.) and Atlanta Clinical Research Center (N.S.), Atlanta — all in Georgia; University of Maryland School of Medicine, Baltimore (K.K., K.N.), and National Institute of Allergy and Infectious Diseases, Bethesda (D.F., M.M., J. Mascola, L.P., J.L., B.S.G.) — both in Maryland; Saint Louis University School of Medicine, St. Louis (S.F.); University of Illinois, Chicago, Chicago (R.N.); George Washington University School of Medicine and Health Sciences, Washington, DC (D.D.); University of California, San Diego, San Diego (S.A.S.); Vanderbilt University School of Medicine, Nashville (C.B.C.); Quality of Life Medical and Research Center, Tucson, AZ (J. McGettigan); Johnson County Clin-Tr...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-04
- Volume
- 384
- Issue
- 5
- Pages
- 403-416
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7787219
- OpenAlex
- W3113734454
- Cited by
- 10,119
- References
- 24
- Citations by year
- 2026: 622 · 2025: 962 · 2024: 1186 · 2023: 1691 · 2022: 2854 · 2021: 2793
- FWCI
- 240.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (ACTG Leadership and Operations Center UM1 AI 68636, HPTN Leadership and Operations Center UM1 AI 68619, HVTN Laboratory Center UM1 AI 68618, HVTN Leadership and Operations Center UM1 AI 68614, HVTN Statistics and Data Management Center UM1 AI, IDCRC leadership group 5 UM1 AI148684-03)
- Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (Contract No. 75A50120C00034)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccines, vaccine efficacy, vaccine safety, reactogenicity, adverse events, vulnerable populations, older adults, immunocompromised patients, breakthrough infection, severe COVID-19 prevention
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult, Patient Acuity, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.